It is not intended for human consumption, medical diagnosis, treatment, or prevention of any disease
These can often be managed with simple measures (e.g., analgesic for headache, proper injection technique for site pain)
Together they can strain the kidneys and cause dizziness, headache, and nausea, symptoms that can be mistaken for ordinary GLP-1 side effects
Under this structure, safety oversight depends on clinician judgment and pharmacy compliance, while the platform remains an administrative access layer
Monitoring at 6 to 8 Weeks Recheck ALT, AST, fasting glucose, and IGF-1 six to eight weeks after starting therapy
This OGD/R model simulates the conditions of cerebral ischemia-reperfusion injury in vitro